{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:59:06Z","timestamp":1785265146803,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472998"],"award-info":[{"award-number":["82472998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["242102311031"],"award-info":[{"award-number":["242102311031"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115806","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:45:44Z","timestamp":1762659944000},"page":"115806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC"],"prefix":"10.1016","volume":"168","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2025.115806_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"17","key":"10.1016\/j.intimp.2025.115806_bb0015","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115806_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.intimp.2025.115806_bb0025","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.intimp.2025.115806_bb0030","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2025.115806_bb0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474086.2024.2420614","article-title":"Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia","volume":"17","author":"Colonne","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.intimp.2025.115806_bb0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2025.115806_bb0045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41409-018-0423-y","article-title":"Successful treatment of two relapsed\/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells","volume":"54","author":"Qu","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.intimp.2025.115806_bb0050","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41375-020-0719-y","article-title":"Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells","volume":"34","author":"Danylesko","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.intimp.2025.115806_bb0055","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115806_bb0060","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.115806_bb0065","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2025.115806_bb0070","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2025.115806_bb0075","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.hoc.2023.06.004","article-title":"Chimeric antigen receptor T cells in acute myeloid Leukemia","volume":"37","author":"Cummins","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.intimp.2025.115806_bb0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA-Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.intimp.2025.115806_bb0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chinese Med J-Peking"},{"issue":"24","key":"10.1016\/j.intimp.2025.115806_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246021","article-title":"Role of epidermal growth factor receptor-specific CAR-T cells in the suppression of esophageal squamous cell carcinoma","volume":"14","author":"Cheng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2025.115806_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115806_bb0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"issue":"42","key":"10.1016\/j.intimp.2025.115806_bb0105","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.1516991112","article-title":"Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.intimp.2025.115806_bb0110","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.intimp.2025.115806_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132455","article-title":"Expression and prognostic value of a novel B7-H3 (CD276) antibody in acute myeloid leukemia","volume":"16","author":"Stefanczyk","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.intimp.2025.115806_bb0120","first-page":"2646","article-title":"B7-H3 expression associates with tumor invasion and patient\u2019s poor survival in human esophageal cancer","volume":"7","author":"Chen","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2025.115806_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1054458","article-title":"The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients","volume":"12","author":"Villar","year":"2022","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2025.115806_bb0130","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1097\/CM9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: from prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0135","doi-asserted-by":"crossref","first-page":"2282250","DOI":"10.1080\/2162402X.2023.2282250","article-title":"A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC","volume":"12","author":"Wu","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2025.115806_bb0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther.-Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115806_bb0145","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115806_bb0150","series-title":"\u2018Diagnostics of Molecular Markers in Childhood Acute Leukaemia Using Biochips\u2019. Acute Leukemia - The Scientist\u2019s Perspective and Challenge","author":"Antica","year":"2011"},{"issue":"14","key":"10.1016\/j.intimp.2025.115806_bb0155","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"544","key":"10.1016\/j.intimp.2025.115806_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"issue":"8","key":"10.1016\/j.intimp.2025.115806_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.intimp.2025.115806_bb0170","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 immune checkpoint protein in human cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2025.115806_bb0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14712598.2021.1862791","article-title":"B7-H3 targeted antibody-based immunotherapy of malignant diseases","volume":"21","author":"Michelakos","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.115806_bb0180","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115806_bb0185","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115806_bb0190","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.115806_bb0195","doi-asserted-by":"crossref","first-page":"11987","DOI":"10.1080\/21655979.2021.2001182","article-title":"Expression characteristic of and in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1027396714623","article-title":"Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72","volume":"17","author":"Blanco","year":"1997","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115806_bb0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115806_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"20 Pt 1","key":"10.1016\/j.intimp.2025.115806_bb0215","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115806_bb0220","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2025.115806_bb0225","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cam4.522","article-title":"B7-H3 protein expression in acute myeloid leukemia","volume":"4","author":"Guery","year":"2015","journal-title":"Cancer Med.-US"},{"issue":"4","key":"10.1016\/j.intimp.2025.115806_bb0230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1179\/1607845414Y.0000000186","article-title":"Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia","volume":"20","author":"Hu","year":"2015","journal-title":"Hematology"},{"issue":"26","key":"10.1016\/j.intimp.2025.115806_bb0235","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0240","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40001-023-01049-y","article-title":"B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia","volume":"28","author":"Fan","year":"2023","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.115806_bb0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.intimp.2025.115806_bb0260","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115806_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1391954","article-title":"The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas","volume":"15","author":"Holzmayer","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115806_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01050-6","article-title":"Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody","volume":"14","author":"Stefanczyk","year":"2024","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.intimp.2025.115806_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:37:06Z","timestamp":1781897826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925017941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"alternative-id":["S1567576925017941"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115806","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115806"}}